Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Rhea-AI Summary
Vanda Pharmaceuticals (Nasdaq: VNDA) will announce fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 after market close. Management will host a conference call at 4:30 PM ET the same day and a simultaneous webcast will be available and archived on the company website.
Investors should register on the website at least 15 minutes early. Call-in numbers use passcode 8728050. A replay will be available beginning Feb 11, 2026 at 8:30 PM ET through Feb 18, 2026 at 11:59 PM ET with listed replay numbers.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VNDA declined 4.87%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VNDA fell 5.59% while peers like TNXP (-5.03%), CADL (-3.06%), OMER (-2.79%), and LXEO (-4.09%) also traded lower, but no peers appeared in the momentum scanner, suggesting a more stock-specific move than a defined sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | FDA decision letter | Negative | -14.1% | FDA said HETLIOZ jet lag sNDA cannot be approved in current form. |
| Dec 30 | FDA approval | Positive | -2.4% | FDA approved NEREUS to prevent motion-induced vomiting based on pivotal trials. |
| Dec 15 | BLA submission | Positive | +6.4% | Filed BLA for imsidolimab in GPP supported by positive Phase 3 data. |
| Dec 11 | Conference participation | Neutral | -2.2% | Announced participation and presentation timing at J.P. Morgan Healthcare Conference. |
| Dec 04 | Clinical hold lifted | Positive | -0.8% | FDA lifted partial clinical hold on tradipitant and confirmed PDUFA date. |
Recent news shows mixed reactions: clear selloff on negative FDA outcomes and uneven responses to otherwise positive regulatory catalysts.
Over the last few months, VNDA’s key catalysts have been regulatory and clinical. A negative FDA decision on HETLIOZ in jet lag on Jan 8, 2026 coincided with a -14.05% move. By contrast, FDA approval of NEREUS for motion-sickness prevention on Dec 30, 2025 and a BLA submission for imsidolimab on Dec 15, 2025 were positive milestones but saw mixed price reactions. The current earnings-date announcement follows this period of active regulatory and clinical developments.
Market Pulse Summary
This announcement sets the timetable for VNDA’s fourth quarter and full-year 2025 earnings release on February 11, 2026, with a management call at 4:30 PM ET. It follows a series of meaningful regulatory and clinical events, including an FDA setback for HETLIOZ and approval of NEREUS. Investors reviewing the call may focus on how recent product developments and past operating losses, as described in prior filings, shape the company’s financial and strategic trajectory.
AI-generated analysis. Not financial advice.
Conference Call and Webcast to Follow
Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode 8728050.
The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.
A replay of the call will be available on Wednesday, February 11, 2026, beginning at 8:30 PM ET and will be accessible until Wednesday, February 18, 2026, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 8728050.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-february-11-2026-302679562.html
SOURCE Vanda Pharmaceuticals Inc.
FAQ
When will Vanda Pharmaceuticals (VNDA) release Q4 and full year 2025 results?
How can investors join the VNDA conference call on February 11, 2026?
Where will Vanda (VNDA) host the webcast and is registration required?
When and how can I access the replay of VNDA's February 11, 2026 call?
What is the conference call passcode for Vanda (VNDA) earnings on Feb 11, 2026?
What times should investors note for Vanda (VNDA) events on February 11, 2026?
